Antimicrobial Peptides: LL-37, Defensins, and the Post-Antibiotic Era

Antimicrobial peptides (AMPs) represent a class of innate immune effectors under intensive investigation as alternatives to conventional antibiotics. The WHO estimates that antimicrobial resistance (AMR) caused 1.27 million deaths directly and contributed to 4.95 million deaths globally in 2019, with projections reaching 10 million annual deaths by 2050 without intervention. AMPs — evolutionarily ancient host defense molecules — offer a fundamentally different mechanism of microbial killing that may circumvent established resistance pathways. Over 3,300 natural AMPs have been cataloged in the Antimicrobial Peptide Database (APD3), spanning organisms from bacteria to humans.

LL-37 is the only human cathelicidin, a 37-amino-acid peptide (MW 4493.3 Da) cleaved from its precursor protein hCAP18 by proteinase 3. The sequence begins with two leucine residues (LL), and the mature peptide adopts an amphipathic alpha-helical structure in membrane-mimetic environments. LL-37 is expressed by neutrophils, macrophages, epithelial cells, and keratinocytes, and is found in sweat, saliva, wound fluid, and airway surface liquid.

Beyond direct antimicrobial activity, LL-37 functions as an immunomodulator: it recruits immune cells through formyl peptide receptor-like 1 (FPRL1) activation, promotes angiogenesis via VEGF induction, modulates TLR signaling by binding bacterial DNA and LPS, and stimulates wound closure through EGFR transactivation. This dual functionality — direct killing plus immune orchestration — distinguishes LL-37 from conventional antibiotics that target single bacterial processes.

Human defensins are cationic peptides of 29-45 amino acids stabilized by three conserved disulfide bonds. Alpha-defensins (HNP-1 through HNP-4 and HD-5, HD-6) are primarily produced by neutrophils and Paneth cells. HNP-1 (MW 3442 Da) is the most abundant neutrophil granule protein, reaching concentrations of 10 mg/mL in phagolysosomes during bacterial engulfment.

Beta-defensins (HBD-1 through HBD-4) are expressed by epithelial cells across mucosal surfaces. HBD-1 is constitutively expressed, while HBD-2 and HBD-3 are inducible by bacterial contact, IL-1β, and TNF-α. HBD-3 has the broadest antimicrobial spectrum, showing activity against Gram-positive and Gram-negative bacteria, fungi (including Candida albicans), and enveloped viruses. The minimum inhibitory concentrations (MICs) of HBD-3 against Staphylococcus aureus range from 1-5 μg/mL in standard broth microdilution assays.

The primary antimicrobial mechanism of AMPs involves electrostatic interaction with negatively charged bacterial membranes, followed by membrane disruption. Three models describe the disruption process: the barrel-stave model (peptides form transmembrane pores perpendicular to the lipid bilayer), the toroidal pore model (peptides and lipid headgroups together line the pore), and the carpet model (peptides accumulate on the membrane surface until a critical concentration causes micellization and membrane dissolution).

LL-37 primarily acts through the toroidal pore mechanism at physiological concentrations. Defensins, due to their beta-sheet structure and compact disulfide-stabilized fold, interact with membranes differently — HNP-1 forms oligomeric pores while HBD-3 acts more through carpet-like disruption. The selectivity of AMPs for bacterial over mammalian membranes derives from the fundamental difference in membrane composition: bacterial membranes are rich in anionic phospholipids (phosphatidylglycerol, cardiolipin), while mammalian cell membranes present predominantly zwitterionic phosphatidylcholine and cholesterol.

• Barrel-stave: peptides insert perpendicularly, forming protein-lined pores
• Toroidal pore: peptides and lipids together form pore lining (LL-37 primary mechanism)
• Carpet model: surface accumulation to critical concentration, then membrane dissolution
• Selectivity: cationic AMPs attracted to anionic bacterial membranes, not zwitterionic mammalian membranes
• Additional intracellular targets: DNA binding, ribosome inhibition, cell wall synthesis disruption

A common argument for AMP development is that bacteria cannot easily develop resistance to membrane-disrupting agents because altering membrane lipid composition would compromise bacterial viability. However, this view oversimplifies the evolutionary dynamics. Bacteria have evolved multiple AMP resistance strategies: modification of LPS with 4-amino-4-deoxy-L-arabinose (reducing net negative charge), production of proteases that degrade AMPs, efflux pump upregulation, capsule production that physically shields the membrane, and release of decoy membrane vesicles.

Serial passage experiments have demonstrated that bacteria can develop 4-8 fold increases in MIC against LL-37 over 500-700 generations. While this rate is slower than resistance development to conventional antibiotics (which can occur in 10-20 generations), it is not negligible. Combination strategies — AMPs with conventional antibiotics — may reduce resistance emergence, as simultaneous resistance to two distinct mechanisms is statistically less likely.

Biofilms — structured bacterial communities embedded in extracellular polymeric substance (EPS) — are 100-1000 fold more resistant to conventional antibiotics than planktonic cells. AMPs show particular promise against biofilms through multiple mechanisms: disruption of the EPS matrix, prevention of initial bacterial attachment, and direct killing of metabolically dormant persister cells within the biofilm.

LL-37 has been shown to inhibit Pseudomonas aeruginosa biofilm formation at sub-MIC concentrations (1/16 MIC) by downregulating genes required for biofilm architecture (including rhlAB and las quorum sensing systems). At higher concentrations, LL-37 disrupts pre-formed biofilms by destabilizing the EPS matrix. HBD-3 similarly shows anti-biofilm activity against Staphylococcus epidermidis at concentrations of 5-20 μg/mL, reducing biofilm biomass by 60-80% in crystal violet assays.

Despite decades of research, only a handful of AMP-derived therapeutics have reached late-stage clinical development. The challenges include: systemic toxicity at therapeutic concentrations, proteolytic instability in serum, high manufacturing costs for peptides relative to small molecules, and difficulty achieving therapeutic concentrations at infection sites. As of 2026, the clinical pipeline includes:

• Pexiganan (MSI-78): Magainin analog for diabetic foot ulcers. Completed Phase III but failed to show superiority over oral ofloxacin. FDA approval not granted.
• OP-145 (P60.4Ac): LL-37-derived peptide for chronic otitis media. Phase II completed with positive efficacy signals.
• Surotomycin (CB-183,315): Cyclic lipopeptide for C. difficile infection. Phase III completed but did not meet primary endpoint versus vancomycin.
• Murepavadin (POL7080): Peptidomimetic targeting LptD in P. aeruginosa. Phase III for ventilator-associated pneumonia paused due to nephrotoxicity signals.
• Brilacidin: Defensin mimetic (non-peptide). Phase II for acute bacterial skin infections completed with positive results.

The trend is toward modified AMPs (D-amino acid substitutions, PEGylation, lipidation) and peptidomimetics that retain antimicrobial activity while improving pharmacokinetic properties. Topical applications remain more tractable than systemic administration.

Research-grade AMPs require comprehensive analytical characterization. LL-37 (37-mer): HPLC purity ≥95%, MS confirmation at m/z 4493.3 [M+H]⁺, circular dichroism (CD) spectroscopy to confirm alpha-helical content in membrane-mimetic solvents (TFE or SDS micelles). Defensins require disulfide bond mapping to confirm correct folding — misfolded defensins with incorrect disulfide pairing show dramatically reduced activity. All AMPs should be tested for endotoxin contamination (LAL assay), as LPS contamination produces false antimicrobial activity in biological assays.

• Murray CJ et al. (2022). Global burden of bacterial antimicrobial resistance in 2019. Lancet, 399(10325):629-655.
• Vandamme D et al. (2012). LL-37 biology. Cell Immunol, 280(1):22-35.
• Hancock REW, Sahl HG. (2006). Antimicrobial and host-defense peptides. Nat Biotechnol, 24(12):1551-1557.
• Ganz T. (2003). Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol, 3:710-720.
• Overhage J et al. (2008). LL-37 anti-biofilm activity against P. aeruginosa. Infect Immun, 76(9):4176-4182.
• Lazzaro BP et al. (2020). AMP resistance evolution. Science, 368(6497):487-488.
• Wang G et al. (2016). APD3 antimicrobial peptide database. Nucleic Acids Res, 44(D1):D1087-D1093.

Explore detailed chemical profiles and research guides for compounds discussed in this article:

• LL-37: Complete Research Guide → /learn/ll-37-research-guide-chemical-profile

• Read more: What Do Peptides Do in the Body? Hormones, Neurotransmission & Immune Defense → https://www.chemverify.com/learn/what-peptides-do-in-body
• Read more: What Are Peptides Good For? Research Applications Reviewed → https://www.chemverify.com/learn/what-are-peptides-good-for
• Read more: Epithalon and Telomere Research: What the Science Actually Shows → https://www.chemverify.com/learn/epithalon-telomere-research-science-evidence
• Read more: Copper Peptides for Wound Healing Research: GHK-Cu Mechanism Deep Dive → https://www.chemverify.com/learn/copper-peptides-wound-healing-ghk-cu-mechanism